The patient has received prior therapy with bevacizumab, ramucirumab or any PARP inhibitor, including olaparib
Any previous treatment with a PARP inhibitor, including olaparib and/or known hypersensitivity to any of the excipients of study treatment
Any previous treatment with a PARP inhibitor, including olaparib
Prior treatment with any PARP inhibitor
Prior treatment with a PARP inhibitor
Prior treatment with a known PARP inhibitor
Prior treatment with a PARP inhibitor
Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinum-based chemotherapy
Patients must not have received previous treatment with PARP inhibitors
Patients who have received any previous treatment with a PARP inhibitor, including olaparib
Prior treatment with a PARP inhibitor, including olaparib.
Prior PARP inhibitor-based therapy
Any previous treatment with PARP inhibitor, including olaparib
Any previous treatment with a PARP inhibitor, including Olaparib
Prior therapy with any PARP inhibitor, including olaparib
Patients may not have previously received a PARP inhibitor
Prior treatment with a PARP inhibitor
Patients who have received prior therapy with an irinotecan-based or temozolomide-based regimen are eligible; patients who have received prior therapy with a PARP inhibitor other than talazoparib are eligible; however, patients who have progressed on a PARP inhibitor plus irinotecan regimen are not eligible
Any previous treatment with PARP inhibitor, including olaparib.
Any previous treatment with PARP inhibitor, including olaparib.
Prior treatment with a PARP inhibitor in any disease setting
Prior therapy with a PARP inhibitor (e.g., olaparib, talazoparib, veliparib, niraparib, rucaparib)
Have demonstrated progressive disease while taking a PARP inhibitor as a previous therapy. Response to prior PARPi is not required.
Prior PARP therapy could have been administered as either treatment for recurrent disease or as maintenance following prior treatment.
Prior treatment with a PARP inhibitor
Patients are not eligible who have received prior PARP inhibitors (including but not limited to veliparib, talazoparib, rucaparib, and olaparib)
TREATMENT: Patients who have had prior treatment with any PARP inhibitor in combination with temozolomide are ineligible to receive treatment with veliparib on this study; patients who have received prior temozolomide or PARP inhibitor with or without other chemotherapy/targeted agent aside from temozolomide should not be excluded solely because of receiving prior PARP inhibitor or temozolomide, unless it was in combination; patients who have received temozolomide with a PARP inhibitor in the past are eligible to participate but will not receive veliparib with temozolomide on study; such patients are eligible to receive other treatment regimens on study based on identified genetic mutations
Prior treatment with a PARP inhibitor or topotecan
No previous treatment with the specific assigned study drug or any other PARP inhibitor
Any previous treatment with PARP inhibitor, including olaparib
Patients may not have previously received a PARP-inhibitor
Prior use of PARP-inhibitors
No line limit on prior therapies as long as the patient meets all other eligibility criteria; patients who have received prior PARP inhibitors and/or PI3kinase inhibitors are allowed to participate on the dose escalation portion; prior PARP inhibitors and/or PI3Kinase inhibitors excludes patients from the dose expansion cohort, but TNBC patients with BRCA mutations can go on if they had previously received a PARP inhibitor
History of grade 3 or 4 toxicities with previous PI3kinase inhibitor or PARP inhibitor exposure with the exception of hematologic toxicities
PARP inhibitor exposure:\r\n* Part A: Patients who have received prior therapy with a PARP inhibitor, with the exception of BMN 673, are eligible; however, patients who have progressed on a PARP inhibitor and temozolomide regimen are not eligible\r\n* Part B and Part C: Patients who have previously been exposed to a PARP inhibitor are not eligible
Phase 1 (Part A): patients who have progressed on a PARP inhibitor and temozolomide regimen are not eligible
Phase 2 (Part B and Part C): patients who have previously been exposed to a PARP inhibitor are not eligible
Any previous treatment with a PARP inhibitor, including olaparib
Prior treatment with veliparib (ABT-888) or other PARP inhibitors (e.g., olaparib)
Patients must not have had prior exposure to any agent with a PARP inhibitor (e.g., veliparib, olaparib, rucaparib, niraparib, talazoparib [BMN 673]) as its primary pharmacology
Patient has had prior treatment with a known PARP inhibitor
Prior therapy with PARP inhibitors.
Prior treatment with a PARP inhibitor (not including iniparib)
Prior treatment with PARP inhibitors (Patients in Cohort A1)
Patients must not have received prior PARP inhibitor therapy including, but not limited to ABT-888, olaparib, rucaparib, and talazoparib (BMN637)
Any previous treatment with a Polyadenosine 5'diphosphoribose polymerisation (PARP) inhibitor, including olaparib.
Prior enrollment into a clinical trial of a PARP inhibitor
Prior treatment with any PARP inhibitor, including rucaparib. Patients who received prior iniparib are eligible.
Prior treatment with a PARP inhibitor
Prior treatment with any PARP inhibitor
Previous treatment with PARP inhibitor. For this study, BSI-201 (iniparib) is not considered as PARPi
Prior treatment with a PARP inhibitor
Prior treatment with a PARP inhibitor
Prior treatment with PARP inhibitor.
Any previous treatment with a PARP inhibitor, including olaparib.
Receipt of PARP inhibitor prior to RT.
Any previous treatment with PARP inhibitor, including olaparib, for the treatment of small cell lung cancer.
Prior treatment with a PARP inhibitor.
Prior treatment with any PARP inhibitor.
Any previous treatment with a PARP inhibitor, including olaparib;
Patients must be at least 4 weeks from the last dose of prior PARP inhibitor
Prior treatment with a known PARP inhibitor
Patient has received treatment previously with a PARP inhibitor.
Prior exposure to ABT888 or other PARP inhibitors is permitted in all cohorts except the cohort evaluating BRCA-mutated PARP inhibitor naive patients, where prior PARP inhibitor treatment will not be permitted; prior exposure to cyclin-dependent kinase inhibitors other than SCH727965 is permitted
Prior or ongoing treatment with a PARP1 inhibitor